Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of the IRX-2 regimen as neoadjuvant and adjuvant therapy for oral cavity squamous cell carcinoma
2016-000373-21Phase 2Terminated
- Sponsor
- IRX Therapeutics, Inc.
- Start
- Aug 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of citoplurikin in Oral Mucosal Carcinoma (2 arms), sponsored by IRX Therapeutics, Inc. Primary endpoint: event-free survival. Started Aug 2016; status: terminated.
02
Drugs
citoplurikin
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on 2016-000373-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000373-21.